Resource to Advance Pediatrics and HIV Prevention Science (RAPPS): Quality Assurance/Quality Control (QA/QC) Support

推进儿科和艾滋病毒预防科学 (RAPPS) 的资源：质量保证/质量控制 (QA/QC) 支持

• 批准号: 10850722
• 负责人: PETER SILVERA
• 金额: $ 51.72万
• 依托单位: ADVANCED BIOSCIENCE LABORATORIES, INC.
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-04-15 至 2024-04-14
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10850722
• 关键词: AIDS prevention; Area; Collaborations; Communities; Contraceptive Agents; Contracts; Development; Devices; Documentation; Extramural Activities; HIV; Investigator-Initiated Research; National Institute of Allergy and Infectious Disease; Pediatrics; Prevention; Private Sector; Quality Control; Research; Resources; Science; Services; Support Contracts; co-infection; meetings; novel therapeutics; pre-clinical; product development; quality assurance; research clinical testing; research study; therapeutic development

The objective of the Resource to Advance Pediatrics and HIV Prevention Science contracts is to provide the extramural scientific community with research materials and preclinical product development support for candidate products that emerge from investigator-initiated research studies, or from collaborations with private sector or academic partners. These services may also be used to support product discovery and development leading to IND, Investigational Device Exemption (IDE), and/or New Drug Application (NDA) filings with the FDA. NIAID will primarily use these contracts to fill critical development and resource gaps more rapidly and efficiently and advance promising products into clinical testing. The focus of these contracts will be development of therapeutics and prevention products for HIV, including single or combination products with activity against associated co-infections or MPTs that incorporate contraceptives.

“促进儿科学和艾滋病预防科学资源”合同的目的是为校外科学界提供研究材料和临床前产品开发支持，以支持从制药商发起的研究中出现的候选产品，或 与私营部门或学术合作伙伴的合作。这些服务还可用于支持产品发现和开发，从而向FDA提交IND、试验用器械豁免（IDE）和/或新药申请（NDA）。NIAID将主要使用这些合同来填补 更快、更有效地解决关键的开发和资源缺口问题，并将有前途的产品推向临床测试。这些合同的重点将是开发艾滋病毒的治疗和预防产品，包括具有抗相关合并感染或含有避孕药的MPT活性的单一或组合产品。